Zomig en es it fr

Zomig Brand names, Zomig Analogs

Zomig Brand Names Mixture

  • No information avaliable

Zomig Chemical_Formula


Zomig RX_link


Zomig fda sheet

Zomig FDA

Zomig msds (material safety sheet)

Zomig Synthesis Reference

No information avaliable

Zomig Molecular Weight

287.357 g/mol

Zomig Melting Point

No information avaliable

Zomig H2O Solubility

No information avaliable

Zomig State


Zomig LogP


Zomig Dosage Forms

Spray; Tablet

Zomig Indication

For the acute treatment of adult migraine (with or without auras)

Zomig Pharmacology

Zolmitriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Zolmitriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT1D family) having only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Zolmitriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Zolmitriptan in humans.

Zomig Absorption


Zomig side effects and Toxicity

No information avaliable

Zomig Patient Information

No information avaliable

Zomig Organisms Affected

Humans and other mammals